Table 1.
Articles Included in Review
| Authors | Study design | N | Control group | Objectives | Year |
|---|---|---|---|---|---|
| Kok et al | population-based cohort | 2,266 | Yes | to confirm the association between endometriosis and cancer is desirable | 2015 |
| Acién et al | Cross-sectional; chart review | 192 | No | To determine the prevalence of endometriosis in EOC patients and the associations between histologic subtypes and endometrial carcinoma. | |
| Matsumoto et al | Cross-sectional; Histologic and immunohistochemical analyses followed by analysis of mutations in β-catenin and PIK3CA genes | 83 | No | To determine the molecular mechanisms in early stages of ovarian endometrioid carcinoma and ovarian clear cell carcinoma, in patients with endometriosis. | 2015 |
| Worley Jr et al | Cross-sectional; Immunohistochemical analysis | 175 | No | To analyze malignant ovarian neoplasms in women with ovarian endometriosis through immunohistochemistry (IHQ), in order to discover potential molecular biomarkers. | 2015 |
| Lee et al | Historical cohort | 239,385 | Yes | To test the hypothesis that different diagnostic criteria for endometriosis can influence its prevalence rate and, as a consequence, the risk of EOC development. | 2015 |
| Guo et al | Cross-sectional study; histologic and immunohistochemical analyses | 74 | Yes | To investigate the role of epigenetic inactivation of RUNX3 in the malignant transformation of ovarian endometriosis. | 2014 |
| Scarfone et al | Retrospective cohort | 73 | Yes | To compare the clinical features and prognosis of carcinomas associated or not with endometriosis, according to histologic subtype. | 2014 |
| Chene et al | Retrospective cohort | 179 | Yes | To investigate the presence of genetic mutations in ovarian endometrioid and clear cell carcinomas, comparing them to benign ovarian cysts. | 2015 |
| Davis et al | Retrospective cohort | 67 | Yes | To compare patients with ovarian clear cell and endometrioid carcinomas to patients with papillary serous carcinoma regarding clinical features, response to treatment, recurrence rates and survival rates. | 2014 |
| Buis et al | historic cohort | 8,904 | Yes | 2013 | |
| Lowery et al | Case-control | 212 | Yes | To validate the hypothesis that loss of BAF250a expression is common in ovarian clear cell and endometrioid carcinomas, and to determine if this event is associated with clinical and epidemiological features. | 2012 |